Psychopharmacological Aspects of Antidementia Agents

  • Stephen Curran
  • Ian Hindmarch


Psychopharmacologists are interested in measuring psychoactive drug-induced changes in cognitive and/or psychological behavior (Hindmarch and Stonier, 1987; 1989; Hindmarch et al., 1988). The number of tests included in a test battery should be kept to a minimum to avoid identifying significant results by chance, and individual tests should be appropriate for the particular psychological function under investigation, e.g., psychomotor performance, information processing capacity (IPC)/CNS integration, and memory (Hindmarch and Wattis, 1988). It is frequently unclear what a particular test is supposed to be measuring (Adams, 1974; Lahtinen et al., 1978). Pre-experimental screening of subjects and the control of confounding variables will also increase the sensitivity of psychometric measures and facilitate the interpretation of results.


Choice Reaction Time Ergot Alkaloid Psychomotor Performance Critical Flicker Fusion Critical Flicker Frequency 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Adams RG (1974): Pre-sleep ingestion of two hypnotic drugs and subsequent performance. Psychopharmacologica 40:185–190CrossRefGoogle Scholar
  2. Alford C, Hindmarch I (1990): Measuring the effects of psychoactive drugs, with particular reference to anti-depressants. In: Microcomputers, Psychology and Medicine, West R, Christie M, Weinman J, eds. John Wiley and Sons, pp. 85–95Google Scholar
  3. Ballinger BR, Reid AH, Heather BB (1982): Cluster analysis of symptoms in elderly demented patients. British Journal of Psychiatry 140:257–262CrossRefGoogle Scholar
  4. Barlow DH, Baer DJ (1967): Effect of cigarette smoking on the critical flicker frequency of heavy and light smokers. Perception and Motor Skills 24:151–155CrossRefGoogle Scholar
  5. Bazo AJ (1973): An ergot alkaloid preparation (Hydergine) versus papaverine in treating common complaints of the aged: a double-blind study. Journal of the American Geriatric Society 11:63Google Scholar
  6. Benscath P, Debreczeni L, Takacs L (1976): Effect of ethyl apovincaminate on cerebral circulation of dogs under normal conditions and in arterial hypoxia. Arzneimittelforschung (Drug Research) 26:1920–1923Google Scholar
  7. Bhatti JZ, Hindmarch I (1987): Vinpocetine effects on cognitive impairments produced by flunitrazepam. International Clinical Psychopharmacology 2(4): 325–331CrossRefGoogle Scholar
  8. Botwinik J (1973): Cognitive Processes in Maturity and Old Age. New York: SpringerGoogle Scholar
  9. Botwinik J, Storandt M (1974): Cardiovascular status, depressive affect and other factors in reaction time. Journal of Gerontology 29:343–348Google Scholar
  10. Busse EW (1978): Duke longitudinal study: senescence and senility. In: Alzheimer’s Disease, Senile Dementia and Related Disorders, Katz R, Terry RD, Bick KL, eds. New York: Raven Press, pp. 59–69Google Scholar
  11. Chui HC, Teng EL, Henderson VW, Moy AC (1985): Clinical subtypes of dementia of the Alzheimer type. Neurology 35:1544–1550Google Scholar
  12. Chui HC (1987): The significance of clinically defined subgroups of Alzheimer’s disease. Journal of Neural Transmission 24:57–68Google Scholar
  13. Coleston DM, Hindmarch I (1988): Possible memory enhancing properties of Vinpocetine. Drug Development Research 14:191–193CrossRefGoogle Scholar
  14. Cowburn RF, Hardy JA, Roberts PJ (1989): Neurotransmitter deficits in Alzheimer’s disease. In: Alzheimer’s Disease: Towards an Understanding of the Pathogenesis, Davies DC, ed. London and Paris: John Libbey, pp. 9–32Google Scholar
  15. Curran S, Wattis JP (1989): Round-up: searching for the cause of Alzheimer’s disease. Geriatric Medicine 19(3): 13–14Google Scholar
  16. Curran S, Wattis JP, Shillingford C, Hindmarch, I (1990): Critical flicker fusion in normal elderly subjects; a cross-sectional community study. Current Research and Reviews in Psychology (in press).Google Scholar
  17. Curran S (1990): Critical flicker fusion techniques in psychopharmacology. In: Human Psychopharmacology: Measures and Methods, Volume 3, Hindmarch I, Stonier PD, eds. Chichester: John Wiley and SonsGoogle Scholar
  18. Davies DC (1989): Alzheimer’s Disease: Towards an Understanding of the Aetiology and Pathogenesis. London and Paris: John LibbeyGoogle Scholar
  19. Eisdorfer C, Cohen D, Veith R (1980): Current Concepts: The Psychopathology of Aging, Washington: Upjohn, pp. 8–12Google Scholar
  20. Fabricant ND, Rose IW (1951): Effects of smoking cigarettes on flicker fusion threshold of normal subjects. Eye, Ear, Nose and Throat Monthly 30:541–543Google Scholar
  21. Fraser M (1987): Dementia: Its Nature and Management, Chichester: John Wiley and Sons, pp. 38–59Google Scholar
  22. Frewer LJ, Hindmarch I (1988): The effects of time of day, age and anxiety on a choice reaction task. In: Psychopharmacology and Reaction Time, Hindmarch I, Aufdembrinke B, Ott H, eds. Chichester: John Wiley and Sons, pp. 103–114Google Scholar
  23. Giacobini E, Becker R (1988): Current Research in Alzheimer Therapy. New York: Taylor and FrancisGoogle Scholar
  24. Giurgea CE (1982): The nootropic concept and its prospective implications. Drug Development Research 2:441–446CrossRefGoogle Scholar
  25. Hadjiev D, Yancheva S (1976): Rheoencephalographic and psychological studies with ethyl apovincaminate in cerebral vascular insufficiency. Arzneimittelforschung (Drug Research) 26:1947–1950Google Scholar
  26. Hamouz W (1977): The use of pyritinol in patients with moderate to severe organic psychosyndrome. Pharmatherapeutica 1:398–404Google Scholar
  27. Hare M (1978): Clinical check-list for diagnosis of dementia. British Medical Journal, ii:266–267.CrossRefGoogle Scholar
  28. Herrmann WM, Scharer E (1987): Effects and efficiency of nootropics discussed with the example of Pyritinol. In: Higher Nervous Functions, Herrmann WM, ed. Vieweg, pp 81–112.Google Scholar
  29. Hindmarch I, Parrott AC, Lanza M (1979): The effects of an ergot alkaloid derivative (Hydergine) on aspects of psychomotor performance, arousal, and cognitive processing ability. Journal of Clinical Pharmacology 19(11 and 12):726–732Google Scholar
  30. Hindmarch I (1980): Psychomotor function and psychoactive drugs. British Journal of Clinical Pharmacology 10(3): 189–209Google Scholar
  31. Hindmarch I (1982): Critical flicker fusion frequency (CFFF): The effects of psychotropic compounds. Pharmacopsychiatry 15(Suppl. l):44–48CrossRefGoogle Scholar
  32. Hindmarch I, Subhan Z (1985): A preliminary investigation of “Albert 285” (HWA 285) on psychomotor performance, mood, and memory. Drug Development Research 5(4):379–386CrossRefGoogle Scholar
  33. Hindmarch I, Stonier PD (1987): Human Psychopharmacology: Measures and Methods, Vol. 1. Chichester: John Wiley and SonsGoogle Scholar
  34. Hindmarch I, Aufdembrinke B, Ott H (1988): Psychopharmacology and Reaction Time. Chichester: John Wiley and SonsGoogle Scholar
  35. Hindmarch I, Wattis JP (1988): Measuring effects of psychotropic drugs. In: Psychological Assessment of the Elderly, Wattis JP, Hindmarch I, eds., Edinburgh: Churchill Livingstone, pp. 180–197Google Scholar
  36. Hindmarch I, Stonier PD (1989): Human Psychopharmacology: Measures and Methods, Volume II. Chichester: John Wiley and SonsGoogle Scholar
  37. Hindmarch I, Kerr JS, Sherwood N (1990): Effects of nicotine gum on psychomotor performance in smokers and non-smokers. Psychopharmacology 100:535–541CrossRefGoogle Scholar
  38. Hindmarch I, Coleston DM (1990): The psychopharmacological effects of pyriti-nol in normal healthy subjects. Neuropsychobiology (in press)Google Scholar
  39. Hoyer S, Oesterreich K, Stoll KD (1977): Effects of Pyritinol-HCl on blood flow and oxidative metabolism of the brain in patients with Dementia. Arzneimittelforschung (Drug Research) 27:671–674Google Scholar
  40. Karpati E, Szporny L (1976): General and cerebral haemodynamic activity of ethyl apovincaminate. Arzneimittelforschung (Drug Research) 26:1908–1912Google Scholar
  41. Kendall M (1987): Drugs for dementia. In: Dementia, Pitt B, ed. Edinburgh: Churchill Livingstone, pp. 265–280Google Scholar
  42. Knezevic S, Mubrin Z, Risberg J, Vucinic G, Spilich G, Gubarev N, Wannen-Macher W (1989): Pyritinol treatment of SDAT patients: Evaluation by psychiatric and neurological examination, psychometric testing and rCBF measurements. International Clinical Psychopharmacology 4:25–38CrossRefGoogle Scholar
  43. Knox J, Hindmarch I, Wallace MG (1982): Visual analogue scales in assessment of severe mental impairment. British Journal of Clinical Practice 516:12–15Google Scholar
  44. Lahtinen V, Lahtinen A, Pekkola P (1978): The effect of nitrazepam on grip strength, reaction time and subjective evaluation of sleep. Acta Pharmaceutica Toxicologia 42:130–134CrossRefGoogle Scholar
  45. Marsden CD, Harrison MJG (1972): Outcome of investigations of patients with pre-senile dementia. British Medical Journal 1:249–252CrossRefGoogle Scholar
  46. Martin KJ, Vyas S (1987): Increase in acetylcholine concentration in the brain of old rats following treatment with pyrithioxin (Encephabol). British Journal of Pharmacology, 90:561–565Google Scholar
  47. Meyers FH, Jawetz E, Goldfien A (1980): Review of Medical Pharmacology, California, Lange, p. 69Google Scholar
  48. Mayeux R, Stern Y, Spanton S (1985): Heterogeneity in dementia of Alzheimer’s type—Evidence of subgroups. Neurology 35:453–461Google Scholar
  49. Morris JC, Berg L, Fulling K, Torack RM, McKeel DW (1987): Validation of clinical diagnostic criteria in senile dementia of the Alzheimer type. Annals of Neurology 22:122Google Scholar
  50. Neary D, Snowden JS, Bowden DM (1986): Neuropsychological syndromes in presenile dementia due to cerebral atrophy. Journal of Neurology, Neurosurgery and Psychiatry 49:163–174CrossRefGoogle Scholar
  51. Nicolaus BJR (1982): Chemistry and pharmacology of nootropics. Drug Development Research 2:463–474CrossRefGoogle Scholar
  52. Nott PN, Fleminger JJ (1975): Pre-senile dementia: The difficulties of early diagnosis. Acta Psychiatrica Scandinavica 51:210–217CrossRefGoogle Scholar
  53. Ott H, Kranda K (1982): Flicker Techniques in Psychopharmacology, Weinheim and Basel: Beltz VerlagGoogle Scholar
  54. Parrott AC, Hindmarch I (1982): The effects of hydergine upon psychomotor performance, indices of alertness and behavioural ratings in studies involving normal and geriatric subjects. British Journal of Clinical Practice 16:18–20Google Scholar
  55. Rabins PV, Starr LB, Price TR (1984): A two year longitudinal study of mood disorders following stroke: Prevalence and duration at six months follow-up. British Journal of Psychiatry 144:488–492CrossRefGoogle Scholar
  56. Ron MA, Toone BK, Garralda ME, Lishman WA (1979): Diagnostic accuracy in pre-senile dementia. British Journal of Psychiatry 134:161–168CrossRefGoogle Scholar
  57. Rosdy B, Balazs M, Szporny L (1976): Biochemical effects of ethyl apovincam-inate. Arzneimittelforschung (Drug Research) 26:1923–1926Google Scholar
  58. Rossor M (1987): Alzheimer’s disease: neurobiochemistry. In: Dementia, Pitt B, ed. Edinburgh: Churchill Livingstone, pp 140–153Google Scholar
  59. Roubicek J, Geiger C, Abt K (1972): An ergot alkaloid preparation (Hydergine) in geriatric therapy. Journal of the American Geriatric Society 20:222Google Scholar
  60. Sahakian B, Jones G, Levy R, Gray J, Warburton D (1989): The effects of nicotine on attention, information processing, and short-term memory in patients with dementia of the Alzheimer’s type. British Journal of Psychiatry 154:797–800CrossRefGoogle Scholar
  61. Simonson E, Brozek J (1952): Flicker fusion frequency: Background and applications. Physiological Reviews 32:349–378Google Scholar
  62. Sherwood N, Kerr JS, Hindmarch I (1989): The use of nicotine gum in psy-chopharmacological research. Medical Science Research 17:891–892Google Scholar
  63. Skondia, V (1979): Criteria for clinical development and classification of nootropic drugs. Clinical Therapeutics 2:316Google Scholar
  64. Smith JM, Misiak H (1976): Critical flicker fusion (CFF)-and psychotropic drugs in normal human subjects—a review. Psychopharmacology 47:175–182CrossRefGoogle Scholar
  65. Spriet A, Simon P (1985): Methodology of Clinical Drug Trials. Basel: KargerGoogle Scholar
  66. Sternberg S (1969): Memory Scanning: Mental processes revealed by reaction time experiments. American Scientist 57:421–457Google Scholar
  67. Sternberg S (1975): Memory Scanning: New findings and current controversies. Quarterly Journal of Experimental Psychology 27:1–32CrossRefGoogle Scholar
  68. Subhan Z, Hindmarch I (1984): The psychopharmacological effects of Ginkgo biloba extract in normal healthy volunteers. International Journal of Clinical Pharmacology IV(2):89–93Google Scholar
  69. Szobor A, Klein M (1976): Ethyl apovincaminate therapy in neurovascular disease. Arzneimittelforschung (Drug Research) 26:1984–1989Google Scholar
  70. Tazaki Y, Omae T, Kuromaru S et al. (1980): Clinical effect of Encephabol (Pyriti-nol) in the treatment of cerebrovascular disorders. Journal of International Medical Research 8:118–126Google Scholar
  71. Tucker JS (1982): As assessment of the effects of intramuscular hydergine in elderly patients with early dementia using critical flicker fusion threshold. British Journal of Clinical Practice, Symposium Supplement, 16:16–17Google Scholar
  72. Turner P (1968): Critical flicker frequency and centrally acting drugs. British Journal of Ophthalmology 52:245–250CrossRefGoogle Scholar
  73. Venn D (1976): Electroencephalogram and ergot alkaloids. Postgraduate Medical Journal 52(Suppl 1):55Google Scholar
  74. Warwick KM, Eysenck HJ (1963): The effects of smoking on the CFF threshold. Life Sciences 4:219–225CrossRefGoogle Scholar
  75. Wilcock GK (1988): Recent research into dementia. Age and Ageing 17:73–86CrossRefGoogle Scholar
  76. Woodworth RS and Schlosberg H (1958): Experimental Psychology. London: MethuenGoogle Scholar

Copyright information

© Birkhäuser Boston 1992

Authors and Affiliations

  • Stephen Curran
  • Ian Hindmarch

There are no affiliations available

Personalised recommendations